Drugs / KER-065
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07704099 | Sep 2026 → Jul 2029 expected | Duchenne muscular dystrophy | Keros Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-09 | Keros Therapeutics, Inc. | Results Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference kerostx.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-09 | Keros Therapeutics, Inc. | Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference kerostx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KER-065 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07704099 ↗ |
| Route | Subcutaneous | “KER-065 will be administered subcutaneously (SC)” NCT07704099 ↗ |